View by Specialty

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

Liver/Biliary Disorders News

SPONSORED CONTENT
Save
SPONSORED CONTENT
April 05, 2023
1 min read
Save

First patient treated in Takeda’s phase 3 trial for alpha-1 antitrypsin deficiency

First patient treated in Takeda’s phase 3 trial for alpha-1 antitrypsin deficiency

Arrowhead Pharmaceuticals announced that the first patient has been treated in Takeda Pharmaceuticals’ phase 3 clinical trial of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver disease.

SPONSORED CONTENT
April 04, 2023
3 min read
Save

Adenovirus re-emerges as likely culprit in 2022 outbreak of acute hepatitis in children

Adenovirus re-emerges as likely culprit in 2022 outbreak of acute hepatitis in children

A 2022 outbreak of unexplained acute severe hepatitis in children has been linked to a strain of adeno-associated virus 2, supporting the theory that disease pathogenesis results from viral coinfection, according to data reported in Nature.

Trending

UTI
November 11, 2024
3 min read
Save

WikiGuidelines group publishes first new UTI guidance in 14 years

SPONSORED CONTENT
April 03, 2023
2 min read
Save

Time-restrictive eating no more effective than daily calorie restriction in NAFLD

Time-restrictive eating no more effective than daily calorie restriction in NAFLD

Compared with daily calorie restriction, time-restricted eating did not achieve additional benefits for reducing intrahepatic triglyceride content or body fat among patients with nonalcoholic fatty liver disease and obesity.

SPONSORED CONTENT
April 03, 2023
2 min read
Save

No difference between semaglutide, placebo in fibrosis improvement in patients with NASH

No difference between semaglutide, placebo in fibrosis improvement in patients with NASH

Although semaglutide did not “significantly improve” fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, notable improvements were reported in cardiometabolic parameters and markers of liver fat and injury.

SPONSORED CONTENT
March 30, 2023
2 min read
Save

Higher poverty linked to lower rates for surgical resection in colorectal liver metastasis

Higher poverty linked to lower rates for surgical resection in colorectal liver metastasis

Patients in U.S. counties with higher poverty were less likely to undergo liver metastasectomy for colorectal liver metastasis, suggesting that access to surgery for complex gastrointestinal cancers may be affected by social determinants.

SPONSORED CONTENT
March 30, 2023
2 min read
Save

FDA limit on acetaminophen dosage linked to fewer hospitalizations, cases of liver failure

FDA limit on acetaminophen dosage linked to fewer hospitalizations, cases of liver failure

A 2011 FDA mandate, which limited acetaminophen dosage to 325 mg/tablet in prescription acetaminophen and opioid products, correlated with a decrease in yearly hospitalizations and cases of acute liver failure related to toxicity.

SPONSORED CONTENT
March 28, 2023
2 min read
Save

High mortality rates prove lean patients with NAFLD should ‘be taken seriously’

High mortality rates prove lean patients with NAFLD should ‘be taken seriously’

Lean patients with nonalcoholic fatty liver disease had significantly higher mortality than non-lean patients, despite having lower rates of cirrhosis and diabetes, according to research in Alimentary Pharmacology & Therapeutics.

SPONSORED CONTENT
March 20, 2023
11 min read
Save

HCV elimination represents ‘win-win-win’ for patients, public health, cost savings

HCV elimination represents ‘win-win-win’ for patients, public health, cost savings

Every year nearly 3 million patients are diagnosed with hepatitis B and C infections, ultimately leading to 1.1 million deaths worldwide, WHO reported.

SPONSORED CONTENT
March 20, 2023
3 min read
Save

Controlling HCV: ‘The time for political action is here’

Controlling HCV: ‘The time for political action is here’

In 2015, WHO initiated a campaign to eliminate hepatitis B and C worldwide.

SPONSORED CONTENT
March 16, 2023
2 min read
Save

90-day fills for chronic hepatitis B treatments increased patient adherence

90-day fills for chronic hepatitis B treatments increased patient adherence

Being prescribed a 90-day or a “mixed duration” supply of entecavir or tenofovir disoproxil fumarate was associated with higher fill rates among commercially insured patients with chronic hepatitis B, researchers found.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails